CN115896144B - Application of FUS protein as fusion tag, recombinant protein and expression method thereof - Google Patents
Application of FUS protein as fusion tag, recombinant protein and expression method thereof Download PDFInfo
- Publication number
- CN115896144B CN115896144B CN202211267322.3A CN202211267322A CN115896144B CN 115896144 B CN115896144 B CN 115896144B CN 202211267322 A CN202211267322 A CN 202211267322A CN 115896144 B CN115896144 B CN 115896144B
- Authority
- CN
- China
- Prior art keywords
- nucleic acid
- acid element
- protein
- fus
- recombinant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 title claims abstract description 39
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 title claims abstract description 39
- 238000000034 method Methods 0.000 title claims abstract description 32
- 102000003890 RNA-binding protein FUS Human genes 0.000 title claims description 25
- 108090000292 RNA-binding protein FUS Proteins 0.000 title claims description 25
- 230000004927 fusion Effects 0.000 title abstract description 20
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 141
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 130
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 130
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 51
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 51
- 241000196324 Embryophyta Species 0.000 claims abstract description 25
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 12
- 229920001184 polypeptide Polymers 0.000 claims abstract description 11
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 11
- 238000000746 purification Methods 0.000 claims abstract description 10
- 241000589158 Agrobacterium Species 0.000 claims abstract description 9
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 9
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 9
- 239000013612 plasmid Substances 0.000 claims abstract description 9
- 230000001131 transforming effect Effects 0.000 claims abstract description 5
- 230000003321 amplification Effects 0.000 claims abstract description 4
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 4
- 239000007788 liquid Substances 0.000 claims description 11
- 230000001580 bacterial effect Effects 0.000 claims description 10
- 239000013598 vector Substances 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 4
- 230000008595 infiltration Effects 0.000 claims description 3
- 238000001764 infiltration Methods 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 abstract description 17
- 125000003729 nucleotide group Chemical group 0.000 abstract description 17
- 230000002776 aggregation Effects 0.000 abstract description 4
- 238000004220 aggregation Methods 0.000 abstract description 4
- 239000002245 particle Substances 0.000 abstract description 3
- 231100000419 toxicity Toxicity 0.000 abstract description 3
- 230000001988 toxicity Effects 0.000 abstract description 3
- 238000003776 cleavage reaction Methods 0.000 abstract description 2
- 230000007017 scission Effects 0.000 abstract description 2
- 238000000502 dialysis Methods 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 34
- 241000208125 Nicotiana Species 0.000 description 14
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 12
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 9
- 230000017730 intein-mediated protein splicing Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- OJOBTAOGJIWAGB-UHFFFAOYSA-N acetosyringone Chemical compound COC1=CC(C(C)=O)=CC(OC)=C1O OJOBTAOGJIWAGB-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 238000005191 phase separation Methods 0.000 description 4
- 238000001338 self-assembly Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101001003067 Hypocrea jecorina Hydrophobin-1 Proteins 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 108010064851 Plant Proteins Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 108010021843 fluorescent protein 583 Proteins 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 235000021118 plant-derived protein Nutrition 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 210000000473 mesophyll cell Anatomy 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 238000010979 pH adjustment Methods 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000006920 protein precipitation Effects 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 230000012743 protein tagging Effects 0.000 description 2
- 108010054624 red fluorescent protein Proteins 0.000 description 2
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 2
- 229960001225 rifampicin Drugs 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- MSYHGYDAVLDKCE-UHFFFAOYSA-N 2,2,3,3,4,4,4-heptafluoro-1-imidazol-1-ylbutan-1-one Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(=O)N1C=CN=C1 MSYHGYDAVLDKCE-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 108010013369 Enteropeptidase Proteins 0.000 description 1
- 102100029727 Enteropeptidase Human genes 0.000 description 1
- 208000002339 Frontotemporal Lobar Degeneration Diseases 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010051815 Glutamyl endopeptidase Proteins 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101000806601 Homo sapiens V-type proton ATPase catalytic subunit A Proteins 0.000 description 1
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
- 102000007357 Methionine adenosyltransferase Human genes 0.000 description 1
- 108010007784 Methionine adenosyltransferase Proteins 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101710089395 Oleosin Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010030544 Peptidyl-Lys metalloendopeptidase Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 102100037466 V-type proton ATPase catalytic subunit A Human genes 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- 241001080519 Zera Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 101150076598 dnaB gene Proteins 0.000 description 1
- 238000012444 downstream purification process Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- -1 strep II Proteins 0.000 description 1
- 108010059339 submandibular proteinase A Proteins 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention discloses an application of FUS as a fusion tag, recombinant protein and an expression and purification method thereof, wherein the recombinant protein comprises the following components: a first nucleic acid element encoding a nucleotide sequence of FUS; a second nucleic acid element encoding a nucleotide sequence capable of being cleaved enzymatically or chemically; a third nucleic acid element encoding a target sequence for a polypeptide or protein. The expression method comprises the following steps: amplifying nucleic acid fragments, preparing recombinant plasmids, transforming into agrobacterium, performing amplification culture and injecting into plant leaves. Purification methods include dialysis, aggregation, redissolution, cleavage, etc. According to the invention, FUS is used as a fusion tag for the first time, recombinant proteins are expressed in plants, and the FUS fusion proteins can form protein particles in leaves, so that the formed proteins are gathered together, thereby reducing the toxicity of the proteins to plant cells, prolonging the period of producing the proteins by plants, and increasing the yield. The purification can be carried out by controlling the pH value to separate the components, the method is simple, the purity is high, and the cost is low.
Description
Technical Field
The invention relates to the technical field of biology, in particular to application of FUS protein as a fusion tag, recombinant protein and an expression method thereof.
Background
The use of plant bioreactors for large-scale production of recombinant proteins or polypeptides has proven to be a promising system, with the advantages of low cost, high yield, low risk, ease of scale, etc., compared to traditional microbial and mammalian bioreactors, and a variety of valuable recombinant therapeutic or non-pharmaceutical proteins have been expressed in plants and commercially used. To further develop the plant reactor, downstream purification of the target protein from the plant sample (estimated to be 80% of the production cost in the case of therapeutic proteins) is a key factor in the large-scale industrial production of recombinant proteins by plant bioreactors.
Traditional protein purification methods involve expression of the protein of interest in a fusion format fused with affinity tags, including polyhistidine, glutathione S-transferase, maltose binding protein, chitin binding domain, c-myc, strep II, calmodulin binding peptide, and the like. Several new strategies have emerged that simplify downstream protein purification. Oleosin fusion targets the desired protein to an oil body that can be easily separated from the water-soluble portion. hydrophobin-I (HFBI) fusion alters the hydrophobicity of the fusion protein, facilitating purification by a surfactant-based two-phase system. Fusion with the gamma-zein domain (Zera) allows the recombinant protein to form compact, ER-localized protein Particles (PBs). Elastin-like (ELP) consists of a repeating pentapeptide (VPGXG) (X is any amino acid except proline) with temperature sensitive phase change properties. When the temperature is raised to its transition temperature (Tt), the soluble ELP aggregates into an insoluble phase which can be separated by centrifugation. When cold buffer is added, the aggregated ELP can be redissolved and reverted to the soluble phase. The three tags of Zera, ELP and hydrophobin-I all contain hydrophobic regions, which facilitate the formation of PBs from the tag and its fusion proteins by self-assembly (Plant Biotechnol. J. 2017.15:671-673).
The key pathogenic protein FUS (Fused in sarcoma) of the gradually frozen human disease plays a key role in transcriptional regulation, RNA metabolism and DNA damage reaction. FUS mutations are associated with Amyotrophic Lateral Sclerosis (ALS) and rare frontotemporal dementia (frontotemporal lobar dementia, FTLD). The FUS amino-terminal low complexity prion-like domains (prion-like LC domains) can form highly reversible fibrous amyloid proteins by liquid-liquid phase separation in cell-free medium. External pressure stimulus or disease-related mutation can cause disturbance of dynamic phase separation regulation of related pathogenic proteins, leading to liquid-solid phase conversion of the proteins and production of highly stable pathogenic amyloid aggregates. The production and transmission of this highly stable pathological amyloid aggregate is closely related to the development of the corresponding disease.
Disclosure of Invention
The invention aims to solve the technical problem of overcoming the defects of the prior art and providing an application of FUS protein as a fusion tag, recombinant protein and an expression method thereof. Because the FUS protein has liquid-liquid phase separation and self-assembly characteristics, the invention firstly utilizes the FUS protein as a fusion tag to express recombinant protein in plants, and discovers that the FUS protein fusion protein can form protein particles in tobacco leaves so as to gather the formed proteins together, thereby reducing the toxicity of the protein to plant cells, prolonging the period of producing the protein by plants and increasing the yield. The pH can be controlled to separate the purified product, the method is simple, the purity is high, and the cost is low.
In order to achieve the above object, the present invention provides an application of FUS protein as a fusion tag.
Based on a general technical idea, the present invention also provides a recombinant protein, which includes:
a) A first nucleic acid element encoding a nucleotide sequence of a FUS protein;
b) A second nucleic acid element encoding a nucleotide sequence capable of being cleaved enzymatically or chemically;
c) A third nucleic acid element encoding a target sequence for a polypeptide or protein;
the 3 'end of the first nucleic acid element is linked to the 5' end of the second nucleic acid element, and the 3 'end of the second nucleic acid element is linked to the 5' end of the third nucleic acid element;
the 3 'end of the third nucleic acid element is linked to the 5' end of the second nucleic acid element, and the 3 'end of the second nucleic acid element is linked to the 5' end of the first nucleic acid element;
the first nucleic acid element, the second nucleic acid element, and the third nucleic acid element are in the same reading frame.
Based on a general technical idea, the present invention also provides a recombinant protein, which includes:
a) A first nucleic acid element encoding a nucleotide sequence of FUS;
b) A third nucleic acid element encoding a target sequence for a polypeptide or protein;
the 3 'end of the first nucleic acid element is connected with the 5' end of the third nucleic acid element, the 3 'end of the third nucleic acid element is connected with the 5' end of the first nucleic acid element, a site which can be specifically cut by enzyme or chemical reagent is formed, and the first nucleic acid element and the third nucleic acid element are positioned in the same reading frame.
The recombinant protein, further, the FUS protein is FL, FPLD, FPGE or FRB;
the FL is shown as SEQ ID No. 1;
the FPLD is shown as SEQ ID No. 2;
the FPGE is shown as SEQ ID No. 3;
the FRB is shown as SEQ ID No. 4.
In the recombinant protein, the enzyme may be enterokinase, endopeptidase Arg-C, endopeptidase Glu-C, endopeptidase Lys-C, blood coagulation factor Xa, intein Ssp DnaB, intein Sce VMA1, etc. in the nucleotide sequence cleaved by the enzyme;
in the chemically cleaved nucleotide sequence, the chemical means comprises cyanogen bromide cleavage.
The recombinant protein, further, the third nucleic acid element is DsRed or SAM.
Based on a general technical concept, the invention also provides an expression method of the recombinant protein, which comprises the following steps:
s1, amplifying nucleic acid fragments of a first nucleic acid element, a second nucleic acid element and a third nucleic acid element;
s2, connecting the amplified nucleic acid fragments together, and transforming the nucleic acid fragments into a vector to obtain a recombinant plasmid;
s3, transforming the recombinant plasmid into agrobacterium, and screening positive clones;
s4, performing amplification culture on the positive clone to obtain bacterial liquid;
s5, transferring the bacterial liquid into plant leaves for culture by an injection or vacuum infiltration method to obtain the protein.
The expression method further comprises a purification method, wherein the purification method comprises the following steps:
(1) Extracting total protein in plant leaves to obtain total protein extract;
(2) And regulating the pH value of the total protein extract to 7.5-8.0, aggregating and separating out the fusion protein, and collecting the supernatant which is the polypeptide or protein encoded by the third nucleic acid element.
Compared with the prior art, the invention has the advantages that:
(1) The invention provides an application of FUS protein as a recombinant protein fusion tag. The FUS protein has liquid-liquid phase separation and self-assembly characteristics, the FUS protein is used as a fusion tag for the first time, and recombinant protein is expressed in plants.
(2) The invention provides an expression and purification method of recombinant protein, which can simplify the downstream purification process when the recombinant protein is expressed in plants by taking FUS protein as a fusion tag because of the self-assembly characteristic of the FUS protein.
(3) The invention provides an expression method of recombinant protein, which uses FUS protein as fusion tag to gather the expressed fusion protein, thereby reducing toxicity of the recombinant protein to cells, reducing degradation of plant endogenous protease to the recombinant protein, and improving expression quantity of the recombinant protein.
(4) The invention provides an expression method of recombinant protein, which is characterized by simple method, high purity and low cost by controlling pH value in the purification process to separate the recombinant protein.
Drawings
In order to make the objects, technical solutions and advantages of the embodiments of the present invention more clear, the technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings in the embodiments of the present invention.
FIG. 1 is a schematic diagram of the connection principle of FUS as a fusion tag to a target protein in an embodiment of the invention.
FIG. 2 is a schematic representation of the full-length FUS protein and the respective deletion mutants of examples 1, 3, 4, and 5 of the present invention.
FIG. 3 is a graph showing the results of PCR amplification of each of the fragments pCAMBIA2301G-FL-DnaB-DsRed in example 1 of the present invention; m is DNA molecular weight standard in the figure; 1, dnaB;2, FL;3 DsRed.
FIG. 4 is a graph showing the effect of pCAMBIA2301G-FL-DnaB-DsRed in example 1 and SAM in examples 2, 3, 4 and 5 on tobacco expression according to the present invention; in the figure, A is FL-DnaB-DsRed; FL-DnaB-SAM; FPLD-DnaB-SAM; FPGE-DnaB-SAM; e FRB-DnaB-SAM.
FIG. 5 is a Western blot visualization of FL-DnaB-SAM in example 2 of the present invention.
FIG. 6 is a graph showing the results of protein precipitation in example 6 of the present invention.
Detailed Description
The invention is further described below in connection with specific preferred embodiments, but it is not intended to limit the scope of the invention.
The materials and instruments used in the examples below are all commercially available.
Example 1:
the recombinant protein expression vector pCAMBIA2301-RefA1-DnaB-DsRed of the present embodiment comprises:
a) First nucleic acid element encoding the nucleotide sequence of the full-length FUS protein: and FL (FL).
FL-FUS protein (source: homosapiens), genbank accession No. NP-004951, codon optimization thereof, the nucleic acid sequence shown in SEQ ID No.1, specifically:
ATGGCTTCTAATGATTATACTCAACAAGCTACTCAATCTTATGGAGCTTATCCTACTCAACCTGGACAAGGATATTCTCAACAATCTTCTCAACCTTATGGACAACAATCTTATTCTGGATATTCTCAATCTACTGATACTTCTGGATATGGACAATCTTCTTATTCTTCTTATGGACAATCTCAAAATACTGGATATGGAACTCAATCTACTCCTCAAGGATATGGATCTACTGGAGGATATGGATCTTCTCAATCTTCTCAATCTTCTTATGGACAACAATCTTCTTATCCTGGATATGGACAACAACCTGCTCCTTCTTCTACTTCTGGATCTTATGGATCTTCTTCTCAATCTTCTTCTTATGGACAACCTCAATCTGGATCTTATTCTCAACAACCTTCTTATGGAGGACAACAACAATCTTATGGACAACAACAATCTTATAATCCTCCTCAAGGATATGGACAACAAAATCAATATAATTCTTCTTCTGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAAATTATGGACAAGATCAATCTTCTATGTCTTCTGGAGGAGGATCTGGAGGAGGATATGGAAATCAAGATCAATCTGGAGGAGGAGGATCTGGAGGATATGGACAACAAGATAGAGGAGGAAGAGGAAGAGGAGGATCTGGAGGAGGAGGAGGAGGAGGAGGAGGAGGATATAATAGATCTTCTGGAGGATATGAACCTAGAGGAAGAGGAGGAGGAAGAGGAGGAAGAGGAGGAATGGGAGGATCTGATAGAGGAGGATTTAATAAGTTTGGAGGACCTAGAGATCAAGGATCTAGACATGATTCTGAACAAGATAATTCTGATAATAATACTATTTTTGTTCAAGGATTGGGAGAAAATGTTACTATTGAATCTGTTGCTGATTATTTTAAGCAAATTGGAATTATTAAGACTAATAAGAAGACTGGACAACCTATGATTAATTTGTATACTGATAGAGAAACTGGAAAGTTGAAGGGAGAAGCTACTGTTTCTTTTGATGATCCTCCTTCTGCTAAGGCTGCTATTGATTGGTTTGATGGAAAGGAATTTTCTGGAAATCCTATTAAGGTTTCTTTTGCTACTAGAAGAGCTGATTTTAATAGAGGAGGAGGAAATGGAAGAGGAGGAAGAGGAAGAGGAGGACCTATGGGAAGAGGAGGATATGGAGGAGGAGGATCTGGAGGAGGAGGAAGAGGAGGATTTCCTTCTGGAGGAGGAGGAGGAGGAGGACAACAAAGAGCTGGAGATTGGAAGTGTCCTAATCCTACTTGTGAAAATATGAATTTTTCTTGGAGAAATGAATGTAATCAATGTAAGGCTCCTAAGCCTGATGGACCTGGAGGAGGACCTGGAGGATCTCATATGGGAGGAAATTATGGAGATGATAGAAGAGGAGGAAGAGGAGGATATGATAGAGGAGGATATAGAGGAAGAGGAGGAGATAGAGGAGGATTTAGAGGAGGAAGAGGAGGAGGAGATAGAGGAGGATTTGGACCTGGAAAGATGGATTCTAGAGGAGAACATAGACAAGATAGAAGAGAAAGACCTTAT。
b) A second nucleic acid element encoding a nucleotide sequence that is capable of being cleaved enzymatically or chemically: ssp DnaB, an intein, is used to cleave and isolate DsRed.
c) Third nucleic acid element encoding a target sequence of a polypeptide or protein: dsRed, a red fluorescent protein, is expressed macroscopic in plants.
The 3 'end of the first nucleic acid element is linked to the 5' end of the second nucleic acid element, and the 3 'end of the second nucleic acid element is linked to the 5' end of the third nucleic acid element.
The 3 'end of the third nucleic acid element is linked to the 5' end of the second nucleic acid element, and the 3 'end of the second nucleic acid element is linked to the 5' end of the first nucleic acid element.
The first nucleic acid element, the second nucleic acid element, and the third nucleic acid element are in the same reading frame. FIG. 1 is a schematic diagram of the connection principle of FUS as a fusion tag to a target protein in an embodiment of the invention.
The expression method of the recombinant protein pCAMBIA1301G-FL-DnaB-DsRed in the embodiment comprises the following steps:
(1) Primers were designed according to the interfaces of the first nucleic acid element (1#), the second nucleic acid element (2#), and the third nucleic acid element (3#), and PCR amplification was performed according to the design principle shown in FIG. 1.
1.1, designing a primer pair.
Wherein the primer pair for amplifying the first nucleic acid element (1 #) is:
F-1#：cgcggCGTCTCGcatgGCTTCTAATGATTATACTC（SEQ ID NO.5）；
R-1#：cgcgaCGTCTCGtcatATAAGGTCTTTCTCTTCTATC（SEQ ID NO.6）；
the primer pair for amplifying the second nucleic acid element (2 #) is:
F-2#：cgcggCGTCTCGatgaAAATCGAAGAAGGT（SEQ ID NO.11）；
R-2#：cgcggCGTCTCGgttgTGTACAATGATGTCA（SEQ ID NO.12）；
the primer pair for amplifying the third nucleic acid element (3 #) is:
F-3#：cgcgaCGTCTCGcaacATGGCCTCCTCCGAGAACGT（SEQ ID NO.13）；
R-3#：cgcggCGTCTCGagctTCACAGGAACAGGTGGTGGC（SEQ ID NO.14）。
1.2, amplifying by using Q5 DNA polymerase to obtain fragments No.1, no.2 and No.3, wherein a PCR reaction system is as follows:
amplification reaction conditions: 98. c, 10 sec; t,30 sec;72 ℃, 2min, 30 cycles. T is the annealing temperature, t=55 ℃ for #1, t=52 ℃ for #2, t=57 ℃ for # 3.
The PCR electrophoresis results are shown in FIG. 3, which shows the following procedure according to the instructions of the agarose gel DNA recovery kit of Tiangen: fragments 1#1.07kb, 2#0.8kb, and 3#0.7kb were recovered.
(2) The pCAMBIA1301G vector, the first nucleic acid element, the second nucleic acid element and the third nucleic acid element are assembled together in an enzyme digestion enzyme connection mode to obtain the pCAMBIA1301G-FL-DnaB-DsRed recombinant vector.
The reaction system is as follows:
the reaction conditions are as follows: controlling the temperature of the PCR instrument to 37 ℃ for 5 min;16 ℃ for 2min;25 cycles. Finally, the pCAMBIA1301G-FL-DnaB-DsRed recombinant vector is obtained by reacting 1 and h at 16 ℃.
(3) The pCAMBIA1301G-FL-DnaB-DsRed recombinant vector is transformed into DH5 alpha escherichia coli, and the recombinant plasmid is obtained according to the transformation steps of the specification.
(4) The recombinant plasmid was transformed into Agrobacterium C58 by chemical transformation, and positive single colonies were selected with LB solid medium containing rifampicin and kanamycin.
(5) Positive single colonies were picked from the plates, inoculated into 3 mL LB liquid medium with the corresponding antibiotics added, and cultured on a constant temperature shaking table at 28℃at 180r/min until OD600 was 0.6-0.8 (approximately 17 h).
(6) And (5) centrifuging at 3000 rpm for 20 min, and collecting bacterial precipitate.
(7) With AW buffer (10mM MES,pH5.6;10mM MgCl) 2 1mM acetosyringone) and adjust OD660 to 0.1.
(8) Extracting bacterial liquid by using a syringe without a needle, and injecting the bacterial liquid on the back of tobacco leaves growing for 6 weeks. Agrobacterium was transfected into tobacco leaves and cultured for 10 days with the expression effect shown in FIG. 4A.
As can be seen from fig. 4A: dsRed is expressed in a mode of direct expression of tobacco cytoplasmic matrixes or aggregation of protein bodies, and tobacco leaves show macroscopic red aggregation spots which emit fluorescence under ultraviolet irradiation, so that the red aggregation spots are proved to be red fluorescent proteins.
Example 2:
the recombinant protein pCAMBIA1301G-FL-DnaB-SAM of the present example, comprising:
a) First nucleic acid element encoding the nucleotide sequence of the full-length FUS protein: FL (FL);
b) A second nucleic acid element encoding a nucleotide sequence that is capable of being cleaved enzymatically or chemically: ssp DnaB, an intein, is used to cleave and isolate target proteins;
c) Third nucleic acid element encoding a target sequence of a polypeptide or protein: SAM, S-adenosylmethionine synthetase.
The 3 'end of the first nucleic acid element is linked to the 5' end of the second nucleic acid element, and the 3 'end of the second nucleic acid element is linked to the 5' end of the third nucleic acid element.
The first nucleic acid element, the second nucleic acid element, and the third nucleic acid element are in the same reading frame.
The expression method of the recombinant protein pCAMBIA1301G-FL-DnaB-SAM in the embodiment comprises the following steps:
(1) PCR amplification was performed by designing primers based on the interfaces of the first nucleic acid element (1#), the second nucleic acid element (2#), and the third nucleic acid element (3#).
1.1, primers for amplifying the first nucleic acid element, the second nucleic acid element are the same as in example 1, and the pair of primers for amplifying SAM is:
forward primer:cgcgaCGTCTCGcaacATGAACGGTCCGGTTGACGG（SEQ ID NO.15）；
reverse primer:
cgcggCGTCTCGagctTCAGTGGTGGTGGTGGTGGTGAAATACCAGCTTCTTCGGTACTTCC（SEQ ID NO.16）。
1.2, amplifying by using Q5 DNA polymerase to obtain fragments No.1, no.2 and No.3, wherein a PCR reaction system is as follows:
reaction conditions: 98℃for 10 sec;55 ℃,30 sec;67 ℃ for 2min; 72 ℃,10 min,30 cycles.
(2) The pCAMBIA1301G vector, the first nucleic acid element, the second nucleic acid element and the third nucleic acid element are assembled by edge ligation.
The reaction system is as follows:
the reaction conditions are as follows: controlling the temperature of the PCR instrument to 37 ℃ for 5 min;16 ℃ for 2min;25 cycles. Finally, the pCAMBIA1301GFL-DnaB-SAM recombinant vector is obtained by reacting 1 and h at 16 ℃.
(3) The pCAMBIA1301G-FL-DnaB-SAM recombinant vector is transformed into DH5 alpha escherichia coli, and the recombinant plasmid is obtained according to the transformation steps of the specification.
(4) The recombinant plasmid was transformed into Agrobacterium C58 by chemical transformation, and positive single colonies were selected with LB solid medium containing rifampicin and kanamycin.
(5) Positive single colonies are picked from the flat plate, inoculated into LB liquid medium with 3 mL added corresponding antibiotics, and cultured on a constant temperature shaking table at 28 ℃ at 180r/min until the OD600 is 0.6-0.8 (about 17h is needed).
(6) And (5) centrifuging at 3000 rpm for 20 min, and collecting bacterial precipitate.
(7) With AW buffer (10mM MES,pH5.6;10mM MgCl) 2 1mM acetosyringone) and adjust OD660 to 0.1.
(8) Extracting bacterial liquid by using a syringe without a needle, and injecting the bacterial liquid on the back of tobacco leaves growing for 5 weeks. Agrobacterium was transfected into tobacco leaves and cultured for 7 days with the expression effect shown in FIG. 4B. As can be seen from fig. 4B: SAM is highly toxic to plant cells, and after transfection 10, the fusion protein is accumulated in a large amount to cause necrosis of part of mesophyll cells, and leaves are in a pathological state.
(9) Extraction of SAM protein:
9.1 preparation of fresh tobacco leaf discs with a punch 10 discs (about 0.1 g) were placed in a 1.5mL centrifuge tube, added with liquid nitrogen and immediately ground into powder with an electric drill.
9.2, 500. Mu.L of protein extract WE (50 mM Tris-HCl (pH 7.5), 150 mM NaCl,4M Urea,0.1% NP-40, and 1mM PMSF were added fresh) and extracted on ice for 10 min.
9.3, 4 ℃,15000, g, and centrifugation for 15 min.
9.4 transfer supernatant to a new 1.5mL centrifuge tube, centrifuge at 4deg.C, 15000 g, for 15 min.
9.5, collecting the supernatant, namely the total plant protein, and immediately loading the sample or preserving the sample at the temperature of minus 80 ℃ for later use.
9.6, western blot experiments:
the soluble proteins were diluted with 4 Xloading buffer (0.2M Tris-HCI, pH6.8,8% SDS,40% glycerol, 4% beta-mercaptoethanol, 0.4% bromophenol blue). Boiled for 5 min and separated on 15% SDS-PAGE with 15 uL,35 uL protein extract/lane. Total proteins separated by SDS-PAGE were transferred directly to PVDF membrane for immunoblotting without staining. Western blot experiments were performed using primary anti-His-Tag anti-Antibody (CST, cat. # 2365) and secondary anti-Goat anti-rabit IgG-HRP (Santa Cruz, cat. SC-2004). And developed using ECL detection system. The development effect is as shown in fig. 5, and as can be seen from fig. 5: FUS fusion SAM proteins are expressed at the position indicated by the arrow and are aggregated in large quantities.
Example 3:
the recombinant protein expression vector pCAMBIA2301-FPLD-DnaB-SAM of this example, comprising:
a) First nucleic acid element encoding the nucleotide sequence of the full-length FUS protein: FPLD.
FPLD is obtained by deleting mutant FL-FUS protein, and FIG. 2 is schematic diagram of deletion mutant FPLD. The nucleic acid sequence is shown as SEQ ID NO.2, and concretely comprises:
ATGGCTTCTAATGATTATACTCAACAAGCTACTCAATCTTATGGAGCTTATCCTACTCAACCTGGACAAGGATATTCTCAACAATCTTCTCAACCTTATGGACAACAATCTTATTCTGGATATTCTCAATCTACTGATACTTCTGGATATGGACAATCTTCTTATTCTTCTTATGGACAATCTCAAAATACTGGATATGGAACTCAATCTACTCCTCAAGGATATGGATCTACTGGAGGATATGGATCTTCTCAATCTTCTCAATCTTCTTATGGACAACAATCTTCTTATCCTGGATATGGACAACAACCTGCTCCTTCTTCTACTTCTGGATCTTATGGATCTTCTTCTCAATCTTCTTCTTATGGACAACCTCAATCTGGATCTTATTCTCAACAACCTTCTTATGGAGGACAACAACAATCTTATGGACAACAACAATCTTATAATCCTCCTCAAGGATATGGACAACAAAATCAATATAATTCTTCTTCTGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAAATTATGGACAAGATCAATCTTCTATGTCTTCTGGAGGAGGATCTGGAGGAGGATATGGAAATCAAGATCAATCTGGAGGAGGAGGATCTGGAGGATATGGACAACAAGATAGAGGAGGAAGAGGAAGAGGAGGATCTGGAGGAGGAGGAGGAGGAGGAGGAGGAGGATATAATAGATCTTCTGGAGGATATGAACCTAGAGGAAGAGGAGGAGGAAGAGGAGGAAGAGGAGGAATGGGAGGATCTGATAGAGGAGGATTTAATAAGTTTGGAGGA。
b) A second nucleic acid element encoding a nucleotide sequence that is capable of being cleaved enzymatically or chemically: ssp DnaB, an intein, is used to cleave and isolate target proteins.
c) Third nucleic acid element encoding a target sequence of a polypeptide or protein: SAM.
The 3 'end of the first nucleic acid element is linked to the 5' end of the second nucleic acid element, and the 3 'end of the second nucleic acid element is linked to the 5' end of the third nucleic acid element.
The 3 'end of the third nucleic acid element is linked to the 5' end of the second nucleic acid element, and the 3 'end of the second nucleic acid element is linked to the 5' end of the first nucleic acid element.
The first nucleic acid element, the second nucleic acid element, and the third nucleic acid element are in the same reading frame.
The expression method of recombinant protein pCAMBIA2301-FPLD-DnaB-SAM in this example is the same as in example 1, wherein the primer pair for amplifying FPLD is:
forward primer:cgcggCGTCTCGcatgGCTTCTAATGATTATACTC（SEQ ID NO.5）；
reverse primer:cgcgaCGTCTCGtcatTCCTCCAAACTTATTAAATCCTC（SEQ ID NO.7）。
example 4:
the recombinant protein expression vector pCAMBIA1301G-FPGE-DnaB-SAM of this example, comprising:
a) First nucleic acid element encoding the nucleotide sequence of the full-length FUS protein: FPGE.
FPGE is obtained by deleting FL-FUS protein, and FIG. 2 is a schematic diagram of the deletion mutant FPGE. FPGE is FUS photon-like domain (amino acids 1-267 at N-terminus) G156E, i.e., mutation of glycine 156 of FPLD to glutamic acid. The nucleic acid sequence is shown as SEQ ID NO.3, and concretely comprises:
ATGGCTTCTAATGATTATACTCAACAAGCTACTCAATCTTATGGAGCTTATCCTACTCAACCTGGACAAGGATATTCTCAACAATCTTCTCAACCTTATGGACAACAATCTTATTCTGGATATTCTCAATCTACTGATACTTCTGGATATGGACAATCTTCTTATTCTTCTTATGGACAATCTCAAAATACTGGATATGGAACTCAATCTACTCCTCAAGGATATGGATCTACTGGAGGATATGGATCTTCTCAATCTTCTCAATCTTCTTATGGACAACAATCTTCTTATCCTGGATATGGACAACAACCTGCTCCTTCTTCTACTTCTGGATCTTATGGATCTTCTTCTCAATCTTCTTCTTATGGACAACCTCAATCTGGATCTTATTCTCAACAACCTTCTTATGGAGGACAACAACAATCTTATGGACAACAACAATCTTATAATCCTCCTCAAGGATATGAACAACAAAATCAATATAATTCTTCTTCTGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAAATTATGGACAAGATCAATCTTCTATGTCTTCTGGAGGAGGATCTGGAGGAGGATATGGAAATCAAGATCAATCTGGAGGAGGAGGATCTGGAGGATATGGACAACAAGATAGAGGAGGAAGAGGAAGAGGAGGATCTGGAGGAGGAGGAGGAGGAGGAGGAGGAGGATATAATAGATCTTCTGGAGGATATGAACCTAGAGGAAGAGGAGGAGGAAGAGGAGGAAGAGGAGGAATGGGAGGATCTGATAGAGGAGGATTTAATAAGTTTGGAGGA。
b) A second nucleic acid element encoding a nucleotide sequence that is capable of being cleaved enzymatically or chemically: ssp DnaB, an intein, is used to cleave and isolate target proteins.
c) Third nucleic acid element encoding a target sequence of a polypeptide or protein: SAM.
The 3 'end of the first nucleic acid element is linked to the 5' end of the second nucleic acid element, and the 3 'end of the second nucleic acid element is linked to the 5' end of the third nucleic acid element.
The 3 'end of the third nucleic acid element is linked to the 5' end of the second nucleic acid element, and the 3 'end of the second nucleic acid element is linked to the 5' end of the first nucleic acid element.
The first nucleic acid element, the second nucleic acid element, and the third nucleic acid element are in the same reading frame.
The expression method of the recombinant protein pCAMBIA1301G-FPGE-DnaB-SAM in this example is the same as in example 1, wherein the primer pair for amplifying FPGE is:
forward primer: ATAATCCTCCTCAAGGATATGAACAACAAAATCAATATAATTC（SEQ ID NO.8）；
Reverse primer: GAATTATATTGATTTTGTTGTTCATATCCTTGAGGAGGATTAT（SEQ ID NO.9）。
Example 5:
the recombinant protein expression vector pCAMBIA1301G-FRB-DnaB-SAM of this example, comprising:
a) First nucleic acid element encoding the nucleotide sequence of the full-length FUS protein: FRB.
FRB is obtained by deleting mutant FL-FUS protein, and FIG. 2 is a schematic diagram of the deletion mutant FRB. FRB is the N-terminal 1-368 amino acid residue of FUS, the nucleic acid sequence is shown in SEQ ID NO.4, specifically:
ATGGCTTCTAATGATTATACTCAACAAGCTACTCAATCTTATGGAGCTTATCCTACTCAACCTGGACAAGGATATTCTCAACAATCTTCTCAACCTTATGGACAACAATCTTATTCTGGATATTCTCAATCTACTGATACTTCTGGATATGGACAATCTTCTTATTCTTCTTATGGACAATCTCAAAATACTGGATATGGAACTCAATCTACTCCTCAAGGATATGGATCTACTGGAGGATATGGATCTTCTCAATCTTCTCAATCTTCTTATGGACAACAATCTTCTTATCCTGGATATGGACAACAACCTGCTCCTTCTTCTACTTCTGGATCTTATGGATCTTCTTCTCAATCTTCTTCTTATGGACAACCTCAATCTGGATCTTATTCTCAACAACCTTCTTATGGAGGACAACAACAATCTTATGGACAACAACAATCTTATAATCCTCCTCAAGGATATGGACAACAAAATCAATATAATTCTTCTTCTGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAAATTATGGACAAGATCAATCTTCTATGTCTTCTGGAGGAGGATCTGGAGGAGGATATGGAAATCAAGATCAATCTGGAGGAGGAGGATCTGGAGGATATGGACAACAAGATAGAGGAGGAAGAGGAAGAGGAGGATCTGGAGGAGGAGGAGGAGGAGGAGGAGGAGGATATAATAGATCTTCTGGAGGATATGAACCTAGAGGAAGAGGAGGAGGAAGAGGAGGAAGAGGAGGAATGGGAGGATCTGATAGAGGAGGATTTAATAAGTTTGGAGGACCTAGAGATCAAGGATCTAGACATGATTCTGAACAAGATAATTCTGATAATAATACTATTTTTGTTCAAGGATTGGGAGAAAATGTTACTATTGAATCTGTTGCTGATTATTTTAAGCAAATTGGAATTATTAAGACTAATAAGAAGACTGGACAACCTATGATTAATTTGTATACTGATAGAGAAACTGGAAAGTTGAAGGGAGAAGCTACTGTTTCTTTTGATGATCCTCCTTCTGCTAAGGCTGCTATTGATTGGTTTGATGGAAAGGAATTTTCTGGAAATCCTATTAAGGTTTCTTTT。
b) A second nucleic acid element encoding a nucleotide sequence that is capable of being cleaved enzymatically or chemically: ssp DnaB, an intein, is used to cleave and isolate target proteins.
c) Third nucleic acid element encoding a target sequence of a polypeptide or protein: SAM.
The 3 'end of the first nucleic acid element is linked to the 5' end of the second nucleic acid element, and the 3 'end of the second nucleic acid element is linked to the 5' end of the third nucleic acid element.
The 3 'end of the third nucleic acid element is linked to the 5' end of the second nucleic acid element, and the 3 'end of the second nucleic acid element is linked to the 5' end of the first nucleic acid element.
The first nucleic acid element, the second nucleic acid element, and the third nucleic acid element are in the same reading frame.
The expression method of the recombinant protein pCAMBIA1301G-FRB-DnaB-SAM in this example is the same as in example 1, wherein the primer pair for amplifying FPGE is:
forward primer:cgcggCGTCTCGcatgGCTTCTAATGATTATACTC（SEQ ID NO.5）；
reverse primer:cgcgaCGTCTCGtcatAAAAGAAACCTTAATAGGATTTC（SEQ ID NO.10）。
the pCAMBIA1301G-FPLD-DnaB-SAM, pCAMBIA1301G-FPGE-DnaB-SAM and pCAMBIA1301G-FRB-DnaB-SAM prepared in examples 3, 4 and 5 were transformed into tobacco by Agrobacterium, and the expression effect of the protein in tobacco was examined, and the results are shown in (C), (D) and (E) of FIG. 4. As can be seen from the figure: SAM is highly toxic to plant cells, and after transfection 10, the fusion protein is accumulated in a large amount to cause necrosis of part of mesophyll cells, and leaves are in a pathological state. During the experiment, if there is no FUS protein tag fusion, the plant leaves will slowly necrose after 4 days of injection of the relevant agrobacterium.
Example 6:
a method for purifying a recombinant protein comprising the steps of:
(1) 10 plants of tobacco were transfected with pCAMBIA1301G-FL-DnaB-SAM, pCAMBIA1301G-FPLD-DnaB-SAM, pCAMBIA1301G-FPGE-DnaB-SAM, and pCAMBIA1301G-FRB-DnaB-SAM in examples 2 to 5, respectively, by vacuum infiltration, and 50G fresh leaves were harvested after 10 days, respectively.
(2) A total plant protein extract 100 mL was obtained in the same manner as in example 2.
(3) Each tube was subjected to pH adjustment to 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5 with 1M HCL or 1M NaOH dilution, respectively, 5mL extract.
(4) The absorbance was measured with an ultraviolet spectrophotometer at (350 nm) using the total plant protein extract without pH adjustment as a blank. Tobacco that had not been transfected was used as a negative control.
As a result, as shown in FIG. 6, when the pH is greater than 7.5, FL, FPLD, FPGE, FRB fusion SAM protein extract is precipitated; when the pH reached 8, the amount of precipitation was maximum (turbidness at 350nm was Turbidity at 350 nm). The pH of the tobacco without transfection was changed without obvious protein precipitation, which proves that FUS or the deletion mutant thereof can be aggregated and precipitated under certain conditions.
The above description is only of the preferred embodiment of the present invention, and is not intended to limit the present invention in any way. While the invention has been described in terms of preferred embodiments, it is not intended to be limiting. Any person skilled in the art can make many possible variations and modifications to the technical solution of the present invention or equivalent embodiments using the method and technical solution disclosed above without departing from the spirit and technical solution of the present invention. Therefore, any simple modification, equivalent substitution, equivalent variation and modification of the above embodiments according to the technical substance of the present invention, which do not depart from the technical solution of the present invention, still fall within the scope of the technical solution of the present invention.
Claims (2)
1. A method of expressing a recombinant protein encoded by a first nucleic acid element, a second nucleic acid element, and a third nucleic acid element; the first nucleic acid element encodes a FUS protein; the second nucleic acid element encodes an Ssp DnaB; the third nucleic acid element encodes SAM; the FUS protein is FPGE; the FPGE is shown as SEQ ID No. 3;
the first nucleic acid element, the second nucleic acid element, and the third nucleic acid element are in the same reading frame; the 3 'end of the first nucleic acid element is linked to the 5' end of the second nucleic acid element, and the 3 'end of the second nucleic acid element is linked to the 5' end of the third nucleic acid element;
the expression method comprises the following steps:
s1, amplifying nucleic acid fragments of the first nucleic acid element, the second nucleic acid element and the third nucleic acid element;
s2, connecting the amplified nucleic acid fragments together, and transforming the nucleic acid fragments into a vector to obtain a recombinant plasmid;
s3, transforming the recombinant plasmid into agrobacterium, and screening positive clones;
s4, performing amplification culture on the positive clone to obtain bacterial liquid;
s5, transferring the bacterial liquid into plant leaves for culture by an injection or vacuum infiltration method to obtain the protein.
2. The expression method according to claim 1, further comprising a purification method comprising the steps of:
(1) Extracting total protein in plant leaves to obtain total protein extract;
(2) And regulating the pH value of the total protein extract to 7.5-8.0 to enable the fusion protein to be aggregated and separated out, wherein the collected supernatant is the polypeptide or protein encoded by the third nucleic acid element.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211267322.3A CN115896144B (en) | 2022-10-17 | 2022-10-17 | Application of FUS protein as fusion tag, recombinant protein and expression method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211267322.3A CN115896144B (en) | 2022-10-17 | 2022-10-17 | Application of FUS protein as fusion tag, recombinant protein and expression method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115896144A CN115896144A (en) | 2023-04-04 |
| CN115896144B true CN115896144B (en) | 2024-01-02 |
Family
ID=86475254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211267322.3A Active CN115896144B (en) | 2022-10-17 | 2022-10-17 | Application of FUS protein as fusion tag, recombinant protein and expression method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115896144B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012088295A1 (en) * | 2010-12-21 | 2012-06-28 | The Chinese University Of Hong Kong | A cost-effictive method for expression and purification of recombinant proteins in plants |
| CN104755502A (en) * | 2012-10-12 | 2015-07-01 | 清华大学 | Production and purification methods of polypeptide |
| EP3696189A1 (en) * | 2019-02-14 | 2020-08-19 | European Molecular Biology Laboratory | Means and methods for preparing engineered target proteins by genetic code expansion in a target protein selective manner |
| CN111606987A (en) * | 2020-06-03 | 2020-09-01 | 长沙馥新合成生物科技有限公司 | Application of glistening protein as fusion label, recombinant protein and expression method thereof |
-
2022
- 2022-10-17 CN CN202211267322.3A patent/CN115896144B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012088295A1 (en) * | 2010-12-21 | 2012-06-28 | The Chinese University Of Hong Kong | A cost-effictive method for expression and purification of recombinant proteins in plants |
| CN104755502A (en) * | 2012-10-12 | 2015-07-01 | 清华大学 | Production and purification methods of polypeptide |
| EP3696189A1 (en) * | 2019-02-14 | 2020-08-19 | European Molecular Biology Laboratory | Means and methods for preparing engineered target proteins by genetic code expansion in a target protein selective manner |
| CN111606987A (en) * | 2020-06-03 | 2020-09-01 | 长沙馥新合成生物科技有限公司 | Application of glistening protein as fusion label, recombinant protein and expression method thereof |
Non-Patent Citations (5)
| Title |
|---|
| In vivo liquid–liquid phase separation protects amyloidogenic and aggregation-prone peptides during overexpression in Escherichia coli;Bartosz Gabryelczyk等;Protein science;第31卷(第5期);e429页，参见摘要，第2页左栏第2段至第4页右栏第1段，第3页图1，第7页左栏第3段至第10页左栏第1段 * |
| Novel Hydrophobin Fusion Tags for Plant- Produced Fusion Proteins;Lauri Reuter等;PLOS ONE;第11卷(第10期);e0164032页，参见摘要 * |
| RNA-binding protein FUS isoform 1;NP_004951.1;Genbank;参见序列及相关信息部分 * |
| Structure of FUS Protein Fibrils and Its Relevance to Self-Assembly and Phase Separation of Low-Complexity Domains;Dylan T. Murray等;Cell;第171卷(第3期);第615-627页，参加摘要 * |
| The oncogenic transcription factor FUS-CHOP can undergo nuclear liquid–liquid phase separation;Izzy Owen等;Journal of Cell Science;第134卷(第17期);第1-15页，参见摘要，第2页左栏第3段至第13页左栏第2段及图1-6 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115896144A (en) | 2023-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230203109A1 (en) | Fusion polypeptides for target peptide production | |
| EP1930423A1 (en) | Expression vector, transformant having the expression vector introduced therein, and process for production of heterologous protein | |
| CN114381471B (en) | Application of auxiliary protein in recombinant protein production and fusion expression system | |
| CN112375774A (en) | Construction method of engineering strain for recombinant protein expression | |
| CN111378047B (en) | Fusion tag protein for improving protein expression and application thereof | |
| CN115896144B (en) | Application of FUS protein as fusion tag, recombinant protein and expression method thereof | |
| RU2354702C2 (en) | RECOMBINANT PLASMID DNA pHINS11 CODING HYBRID PROTEIN-HUMAN INSULIN PRECURSOR, Escherichia coli CELL, TRANSFORMED WITH RECOMBINANT PLASMID DNA pHINS11, Escherichia coli BACTERIA STRAIN JM109/pHINS11 - PRODUCER OF HYBRID PROTEIN-HUMAN INSULIN PRECURSOR, AND METHOD OF OBTAINING HUMAN INSULIN | |
| CN111363048B (en) | Soluble recombinant tartary buckwheat metallothionein FtMT with membrane penetrating activity and preparation method thereof | |
| CN113980880B (en) | Genetically engineered bacterium and application thereof, and method for producing psicose by taking glucose as raw material | |
| CN113249288B9 (en) | Recombinant bacterium for expressing GLP-1 analogue and application thereof | |
| CN111606987A (en) | Application of glistening protein as fusion label, recombinant protein and expression method thereof | |
| RU2447149C1 (en) | RECOMBINANT PLASMID DNA pMSIN4, CODING HYBRIDE POLYPEPTIDE - HUMAN INSULIN PRECURSOR, BL21(DE3)VpMSIN4-PRODUCER STRAIN OF RECOMBINANT HUMAN INSULIN, METHOD FOR PRODUCING RECOMBINANT HUMAN INSULIN | |
| CN110551205A (en) | mutant of soluble human tumor necrosis factor apoptosis-related inducing ligand and preparation method and application thereof | |
| CN113929757B (en) | Method for enhancing cold tolerance of rice by mutating calcium ion binding protein OsCIP1/2 | |
| CN118240735B (en) | Bacterial strain capable of expressing exogenous protein, recombinant human collagen, synthesis method and application | |
| CN102304518A (en) | Method for preparing human parathyroid hormone 1-34 | |
| CN117286175B (en) | Application of microfilament depolymerizing factor AtADF protein in preparation of high-temperature-resistant plants | |
| KR0149955B1 (en) | Preparation of human glucagon using fusion protein | |
| WO2004031243A9 (en) | Protein polymer and process for producing the same | |
| CN116063571A (en) | Preparation method and application of recombinant SSB antigen | |
| WO2022186063A1 (en) | Method for producing cas3 protein | |
| WO2020087194A1 (en) | Glucan affinity label and application thereof | |
| CN117964708A (en) | Intein and application of mutant thereof | |
| CN116926091A (en) | Aspartic acid aminotransferase as well as preparation method and application thereof | |
| CN116284275A (en) | Intein Ssp tau, coding gene and application thereof in preparation of tetrapeptide-5 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |